Steroid Sparing

Baltimore -- The immunosuppressant agent mycophenolate mofetil (CellCept) should be considered the steroid-sparing drug of choice in the management of pemphigus, according to Daniel Mimouni, M.D.

Related Videos
Related Content

Advancements in Understanding the Skin's Microbiomes

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Narrow-Spectrum Antibiotics: The Precision Medicine of Acne?

March 19th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Advancements in Surgical Scar Revision

March 19th 2023

New Data Shows Promising Results in Treatment of Hand and Foot Atopic Dermatitis

March 19th 2023

Advancements in Understanding the Skin's Microbiomes

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Narrow-Spectrum Antibiotics: The Precision Medicine of Acne?

March 19th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Advancements in Surgical Scar Revision

March 19th 2023

New Data Shows Promising Results in Treatment of Hand and Foot Atopic Dermatitis

March 19th 2023

Advancements in Understanding the Skin's Microbiomes

March 20th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Narrow-Spectrum Antibiotics: The Precision Medicine of Acne?

March 19th 2023

The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice

December 2nd 2021

New Advancements in Surgical Scar Revision

March 19th 2023

New Data Shows Promising Results in Treatment of Hand and Foot Atopic Dermatitis

March 19th 2023
© 2023 MJH Life Sciences

All rights reserved.